ChanTest

NEW YORK (GenomeWeb News) – BioFocus today said that it has signed an agreement to offer ChanTest's cell line library and Channel Panel profiling services.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roched has entered into an agreement with ChanTest to evaluate the safety of potential drug compounds.

ChanTest will develop non-clinical assays, databases, and computational models for assessing the risk of serious cardiac events associated with drug-induced QT prolongation.

Molecular Devices will also sell ChanTest's cell optimization services to Molecular Devices' customers worldwide using its PatchXpress 7000A, IonWorks Quattro, IonWorks Barracuda, and FLIPR Tetra systems.

News Scan

Premium

DiscoveryBioMed, ArtusLabs, Heptares Therapeutics, Gentronix, GlaxoSmithKline, BioFocus DPI, Eli Lilly, Millipore, Epitome, ChanTest, Applied Cell Sciences, BioTime, Embryome Sciences, Reproductive Genetics Institute of Chicago, Arizona State University Biodesign Institute, VisionGate

The acquisition will add ACS' GPCR capabilities to ChanTest's ion channel testing services and validated cell lines.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.